Official blog
Compliance-aware guides and brand updates for adult consumers.
Page 23 of 35 / 832 articles
Decades of exaggerated claims, shifting messaging, and the perception that public health agencies prioritize institutional interests over honest communication have eroded trust in the very institutions that are supposed to guide smokers toward healthier choices.
The technological evolution of vaping devices—from simple cigarette-like devices to powerful, customizable mods to the current generation of disposable and pod-based systems—reflects a market searching for the optimal balance of satisfaction, convenience, and risk. The technology is not neutral with respect to health.
The global nicotine supply chain—concentrated in China and India for active pharmaceutical ingredients, in Shenzhen for hardware, and in the US and EU for brand marketing—is increasingly subject to geopolitical disruption. Tariffs, export controls, and supply-chain nationalism are reshaping the industry.
Nicotine addiction and opioid addiction share neurobiological pathways, behavioral patterns, and—increasingly—treatment approaches. The siloed approach to addiction—tobacco here, opioids there—misses the connections that could make both treatment systems more effective.
Cigarette filters were introduced in the 1950s as a safety innovation, marketed to consumers terrified by the emerging evidence that smoking causes lung cancer. The filters didn't make cigarettes safer. They made them more appealing—and may have made them more dangerous—while creating an environmental disaster.
Schools have responded to the youth vaping 'epidemic' with punitive measures—suspensions, citations, even arrests. The policies are intended to deter. The evidence suggests they push vulnerable students out of school and into the criminal justice system, without reducing vaping.
China consumes 40% of the world's cigarettes, and the state-owned China National Tobacco Corporation is the world's largest cigarette manufacturer. The tension between public health obligations and state revenue interests makes tobacco control in Asia a fundamentally different challenge from the West.
When domestic tobacco regulations threaten the industry's profits, the industry turns to international trade law. A series of WTO disputes—from Australia's plain packaging to Thailand's health warnings—reveal how trade agreements constrain public health sovereignty in ways that are largely invisible to the public.
A growing community of 'biohackers' and productivity enthusiasts are experimenting with nicotine—in gum, lozenge, and patch form—as a cognitive enhancer, without any history of smoking. The practice is scientifically plausible and ethically contested.
Millions of smokers have reduced their cigarette consumption by supplementing with vaping—but haven't quit completely. The public health implications of 'dual use' are fiercely debated. The answer depends on whether dual use is a transitional state or a permanent destination.
Public health campaigns are designed by experts who have never smoked, for populations whose lives they don't share, using messages that don't resonate with the people they're trying to reach. The billion smokers who remain are not a 'problem' to be solved—they're a constituency to be served.
Behind every flavored vape is a global network of flavor chemists, extraction facilities, and regulatory arbitrageurs who turn raw botanicals into the thousands of flavor compounds that define the vaping experience. Their world is largely invisible to regulators—and to consumers.
As cannabis legalization spreads and cigarette consumption declines, the tobacco and cannabis industries are converging—through shared delivery technology, cross-industry investment, and an overlapping consumer base. The regulatory systems for the two substances remain entirely separate, and entirely unprepared.
Nicotine is a chronobiotic—a substance that affects the body's internal clock. Smokers have disrupted sleep architecture, altered circadian gene expression, and a distinctive temporal pattern of craving that peaks in the morning. Understanding the nicotine-circadian connection opens new avenues for cessation support.
An estimated 10-12% of cigarettes consumed globally are illicit—smuggled, counterfeited, or manufactured without tax payment. The illicit trade undermines every tobacco control policy, funds organized crime, and exposes consumers to unregulated products. Addressing it requires confronting uncomfortable truths.
Adolescent risk-taking is not a failure of information—it's a developmental feature. The public health campaigns designed to scare teenagers away from vaping may, in some cases, be making vaping more attractive to the very audience they're trying to reach.
American chewing tobacco—loose-leaf, 'dip,' and moist snuff—remains popular in rural communities, among military personnel, and in certain sports cultures, despite causing oral cancer at rates far higher than Swedish snus. The product's persistence reveals uncomfortable truths about culture, class, and regulation.
Menthol cigarettes account for over a third of the US cigarette market and are disproportionately used by Black smokers. The FDA's proposed menthol ban would be the most significant federal tobacco regulation in decades—with consequences that extend far beyond public health.
People with mental illness consume nearly half of all cigarettes sold in the United States. They are more nicotine-dependent, less likely to be offered cessation support, and more likely to die from smoking-related disease than the general population. The mental health system has largely accepted this as normal.
A vaccine that prevents nicotine from reaching the brain—making smoking unrewarding and relapse impossible—has been the holy grail of addiction medicine since the 1990s. The science is sound. The clinical trials have all failed. What happened?
In 1965, smoking was a habit of the affluent. Today, in high-income countries, it is overwhelmingly concentrated among the poor, the mentally ill, and the socially marginalized. The story of how smoking became a disease of poverty is a story about the limits of public health in the absence of social justice.
In the absence of adequate public health infrastructure for smoking cessation, vape shops have become de facto health clinics—staffed not by medical professionals but by former smokers who guide customers through the transition from cigarettes to vaping. The results are messy, unregulated, and surprisingly effective.
Altria—the parent company of Philip Morris USA, maker of Marlboro—has spent billions trying to diversify beyond cigarettes. The results have been catastrophic: Juul, Cronos, and a series of strategic missteps that raise fundamental questions about whether a cigarette company can meaningfully transform.
Genetic variation explains roughly 50% of the variance in smoking initiation, 60% of the variance in nicotine dependence severity, and 50% of the variance in cessation success. The era of personalized nicotine medicine is approaching—but its ethical implications are largely unexplored.
Products
Select a product to view details, highlights, and technical specifications.
